ABBV vs MRNA
By Alex · Tickerpine
AbbVie Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | MRNA |
|---|---|---|
| Price | $264.34 | $198.88 |
| Market cap | $467.12B | $79.40B |
| P/E ratio | 74.5 | — |
| ROE | — | -39.00% |
| Profit margin | 9.80% | -141.43% |
| Revenue growth | 10.20% | 2.10% |
| Dividend yield | 2.62% | — |
| Beta | 0.28 | 1.11 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs MRNA in plain English
- ABBV is the bigger company — about 5.9× the market cap of MRNA.
- ABBV is growing revenue faster (10% vs 2%).
- ABBV pays a dividend (2.62%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.